Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RY104
- Development stage
- Preclinical
- Lead developer
- Reyon Pharmaceutical
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Ophthalmic, Intravitreal
01
Overview
RY104 (also known as NG101) is an adeno-associated virus (AAV) vector-based gene therapy co-developed by Reyon Pharmaceutical and Neuracle Genetics. The therapy is engineered to deliver a genetic sequence encoding aflibercept, a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF). By facilitating the local, long-term expression of aflibercept, RY104 aims to inhibit pathological angiogenesis and vascular leakage. While its most advanced clinical development is for wet age-related macular degeneration (wAMD), where it has entered Phase 1/2a clinical trials in Canada, Reyon Pharmaceutical's pipeline also identifies RY104 as a candidate for acute neurological and neurodegenerative diseases in the preclinical stage. Reyon Pharmaceutical holds exclusive worldwide manufacturing and supply rights for the product, utilizing its specialized facility in Chungju for global distribution.
- Other names
- AAV-aflibercept gene therapy
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on RY104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RY104.